EGFR and non-small cell lung carcinoma: Evidence is provided that CAF secreted HGF provides resistance to EGFR TKI therapy in NSCLC patients by cytokine crosstalk [99] and CAF subsets mediate de novo resistance to EGFR TKI therapy in EGFRm NSCLC [100].